24/7 Patient Assistance: 760-405-8205

Stephanie Jeske, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. Stephanie Jeske is a board-certified medical oncologist who lives in San Francisco, California. She graduated from the Indiana University School of Medicine and did her residency in internal medicine at the University of Texas Southwestern Medical School. She also did a fellowship in hematology/oncology at the New York Presbyterian Hospital. With nearly 20 years of experience, she currently practices at the St. Luke’s Medical Center. She has also contributed to two research publications.

    Insurance Accepted

    AetnaCignaUnited Healthcare

  • Education & Training


    Indiana University

    Medical School


    University of Texas Southwestern Medical School



    New York Presbyterian Hospital


  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    St. Luke's Medical Center

    Languages: English/Spanish

    (602) 251-8100

    1800 E Van Buren St

    Phoenix, Arizona 85006

    Read More
  • Publications & Memberships

    Dr. Stephanie Jeske has contributed to 2 publications.

    A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.

    Tagawa, S. T., Milowsky, M. I., Jeske, S., Mazumdar, M., Kung, S., Sung, M., Lehrer, D., Matulich, D., Selzer, J., Wright, J. J., Nanus, D. M.; Am J Clin Oncol. 2011 Oct.

    See more >>

    Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

    Jeske, S., Tagawa, S. T., Olowokure, O., Selzer, J., Giannakakou, P., Nanus, D. M.; Urol Oncol. 2011 Nov 01.

    See more >>


    American Society of Clinical Oncology

    American Society of Hematology

    Association of American Physicians